GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sernova Biotherapeutics Inc (OTCPK:SEOVF) » Definitions » Gross Profit

SEOVF (Sernova Biotherapeutics) Gross Profit : $0.00 Mil (TTM As of Jan. 2025)


View and export this data going back to 1998. Start your Free Trial

What is Sernova Biotherapeutics Gross Profit?

Sernova Biotherapeutics's gross profit for the three months ended in Jan. 2025 was $0.00 Mil. Sernova Biotherapeutics's gross profit for the trailing twelve months (TTM) ended in Jan. 2025 was $0.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Sernova Biotherapeutics's gross profit for the three months ended in Jan. 2025 was $0.00 Mil. Sernova Biotherapeutics's Revenue for the three months ended in Jan. 2025 was $0.00 Mil. Therefore, Sernova Biotherapeutics's Gross Margin % for the quarter that ended in Jan. 2025 was N/A%.

Sernova Biotherapeutics had a gross margin of N/A% for the quarter that ended in Jan. 2025 => No sustainable competitive advantage


Sernova Biotherapeutics Gross Profit Historical Data

The historical data trend for Sernova Biotherapeutics's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sernova Biotherapeutics Gross Profit Chart

Sernova Biotherapeutics Annual Data
Trend Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sernova Biotherapeutics Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sernova Biotherapeutics's Gross Profit

For the Biotechnology subindustry, Sernova Biotherapeutics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sernova Biotherapeutics's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sernova Biotherapeutics's Gross Profit distribution charts can be found below:

* The bar in red indicates where Sernova Biotherapeutics's Gross Profit falls into.


;
;

Sernova Biotherapeutics Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Sernova Biotherapeutics's Gross Profit for the fiscal year that ended in Oct. 2024 is calculated as

Gross Profit (A: Oct. 2024 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Sernova Biotherapeutics's Gross Profit for the quarter that ended in Jan. 2025 is calculated as

Gross Profit (Q: Jan. 2025 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Sernova Biotherapeutics's Gross Margin % for the quarter that ended in Jan. 2025 is calculated as

Gross Margin % (Q: Jan. 2025 )=Gross Profit (Q: Jan. 2025 ) / Revenue (Q: Jan. 2025 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Sernova Biotherapeutics  (OTCPK:SEOVF) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Sernova Biotherapeutics had a gross margin of N/A% for the quarter that ended in Jan. 2025 => No sustainable competitive advantage


Sernova Biotherapeutics Gross Profit Related Terms

Thank you for viewing the detailed overview of Sernova Biotherapeutics's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Sernova Biotherapeutics Business Description

Traded in Other Exchanges
Address
700 Collip Circle, Suite 114, London, ON, CAN, N6G 4X8
Sernova Biotherapeutics Inc is a clinical-stage company developing regenerative medicines. The company develops Cell Pouch with human donor cells or stem cells to create a biohybrid organ. The Cell Pouch is a implantable medical device designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells, which then release proteins, hormones, or other factors into the bloodstream for the long-term treatment of multiple chronic diseases such as type 1 diabetes, hypothyroid disease, and rare diseases such as hemophilia A.